| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2009: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Research Abstract |
To investigate the effectiveness of Jak inhibition on systemic lupus erythematosus (SLE), CP690,550, a Jak3 specific inhibitor was utilized. CP690,550 strongly suppressed CD4+ T cell proliferation and production of IFN-・ and IL-17, induced by CD3 and CD28 stimuli, in a dose dependent manner. However, CP690,550 did not affect B cell proliferation, induced by BCR and sCD40L stimuli. Moreover, CP690,550 also suppressed mRNA expression of IFN-・ and IL-17 in a dose dependent manner, but did not induced CD4+ T cell apoptosis. Becasuse previous reports have pointed out the enhanced production of IFN-・ and IL-17 in SLE patient, our results indicate the possible effectiveness of Jak3 inhibition on SLE.
|
